Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Presentation of New Phase 2 DUET Data (RTRX) Nov 21, 2016 06:42AM
Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy' Sep 7, 2016 06:53AM
Roth Capital Affirms Ligand Pharma (LGND) Following Solid Q2 Revenue Results for Promacta (NVS) Jul 19, 2016 10:21AM
Roth Positive on Ligand Pharma (LGND) Amid Another Key OmniAb Collaboration (GILD) Jul 8, 2016 09:47AM
Roth Keeps Ligand Pharma (LGND) at 'Buy' as Kyprolis Receives Expanded Indication in Europe (AMGN) Jul 5, 2016 09:18AM


Apr 20, 2016 12:37PM Orphan Drug Exclusivity for Spectrum's (SPPI) Evomela is Important Increment for Ligand (LGND) - Roth Capital
Apr 7, 2016 07:56AM Roth Remains Bullish on Ligand Pharma (LGND) as Revolade Gets Expanded Approval in Europe (NVS)
May 30, 2014 07:08AM Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary
Apr 14, 2014 01:34PM Roth Affirms Bullish Position on Retrophin (RTRX) Following Financial, Pipeline Updates
Feb 13, 2014 01:48PM Roth Lifts PT on Retrophin (RTRX) to $51; Impressive Manchester Pharma Purchase Will Bolster Business Plan
Jan 10, 2014 08:00AM Retrophin (RTRX) Prices 4.7M Common Offering at $8.50/Share